HanAll Biopharma has stepped up its legal fight with Harbour BioMed, filing a counterclaim with the International Chamber of Commerce (ICC) to formally terminate their licensing deal for the autoimmune drug candidate batoclimab (HL161) and reclaim rights across Greater China.The move, announced Thur

Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Immunovant’s batoclimab failed key TED trials, but high doses helped; focus now shifts to next-gen drug IMVT-1402 for autoimmune disease.

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose...

Immunovant’s batoclimab fails Phase 3 thyroid eye disease trials

Immunovant on Wednesday reported longer-term outcomes of its autoimmune treatment batoclimab in Graves’ disease, though it’s unlikely the company will move the experimental drug forward into further studies.

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

Immunovant’s eye drug batoclimab failed in two late-stage trials in thyroid eye disease (TED), the company disclosed Thursday.

Immunovant on Wednesday reported longer-term outcomes of its autoimmune treatment batoclimab in Graves’ disease, though it’s unlikely the company will move the experimental drug forward into further s...

Immunovant will not seek approval for its candidate for the autoimmune disorder myasthenia gravis (MG), despite a reasonable showing in its pivotal trial. Instead, the company said Wednesday that it w...

Reported Thursday, Apr 2 - 5:05am EDT (TheFly subscription required to read more.)

Reported Wednesday, Mar 19 - 12:26pm EDT (TheFly subscription required to read more.)

Reported Wednesday, Mar 19 - 7:52am EDT (TheFly subscription required to read more.)

The chronic inflammatory demyelinating polyneuropathy market is set to grow significantly by 2036, driven by increased awareness, improved diagnoses, and promising new therapies.

HanAll Biopharma's Batoclimab gains Orphan Drug Designation in Japan, targeting Thyroid Eye Disease. A new phase 3 study is underway.

Immunovant (Nasdaq: IMVT) reported fiscal Q4 and full-year 2026 results and key IMVT-1402 updates. In difficult-to-treat rheumatoid arthritis, Week 16 ACR20/50/70 response rates were 72.7%, 54.5% and 35.8%. A cutaneous lupus trial is fully enrolled, with topline data in 2H 2026. Cash and equivalents of $902.1 million are expected to fund development through potential IMVT-1402 launch in Graves’ disease. Batoclimab development was discontinued after two Phase 3 thyroid eye disease studies did not meet primary endpoints. Full-year net loss was $505.6 million, driven largely by higher IMVT-1402 R&D spending and batoclimab wind-down costs.